Investors Buy Shares of Pfizer (PFE) on Weakness

Traders purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Tuesday. $231.62 million flowed into the stock on the tick-up and $101.22 million flowed out of the stock on the tick-down, for a money net flow of $130.40 million into the stock. Of all stocks tracked, Pfizer had the 4th highest net in-flow for the day. Pfizer traded down ($0.25) for the day and closed at $36.01

A number of analysts recently issued reports on the company. BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. SunTrust Banks reaffirmed a “hold” rating and issued a $40.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Morgan Stanley lifted their target price on Pfizer from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. UBS Group set a $42.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $39.45.

The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $214,650.00, a price-to-earnings ratio of 10.23, a P/E/G ratio of 2.05 and a beta of 0.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter last year, the company posted $0.47 earnings per share. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.78%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is presently 38.64%.

Pfizer declared that its board has approved a share repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

In other news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

Several large investors have recently modified their holdings of the company. Investment Centers of America Inc. boosted its stake in shares of Pfizer by 2.3% in the third quarter. Investment Centers of America Inc. now owns 195,611 shares of the biopharmaceutical company’s stock valued at $6,990,000 after buying an additional 4,472 shares during the period. HL Financial Services LLC boosted its stake in shares of Pfizer by 1.1% in the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after buying an additional 35,744 shares during the period. Hartford Financial Management Inc. boosted its stake in shares of Pfizer by 10.8% in the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 835 shares during the period. Cadence Bank NA boosted its stake in shares of Pfizer by 1.4% in the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 1,428 shares during the period. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its stake in shares of Pfizer by 437.9% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock valued at $27,607,000 after buying an additional 629,361 shares during the period. Institutional investors own 70.12% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/20/investors-buy-shares-of-pfizer-pfe-on-weakness-2.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply